NCT02589717 - An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy | Biotech Hunter

Timeline

Start Date

November 30, 2015

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions

Urothelial Carcinoma

Interventions

DRUG

Atezolizumab [TECENTRIQ]

Atezolizumab 1200 mg will be administered by IV infusion q3w. Initial IV infusion will be given over 60 minutes and subsequent infusions will be given over 30 minutes.

Trial Locations (40)

10016

New York

12208

Abany

14642

Rochester

15212

Pittsburgh

18045

Easton

19107

Philadelphia

22908

Charlottesville

23502

Norfolk

29425

Charleston

33140

Miami Beach

33612

Tampa

39202

Jackson

40202

Louisville

43210

Columbus

46237

Indianapolis

46526

Goshen

48106

Ann Arbor

48202

Detroit

51101

Sioux City

56303

Saint Cloud

60426

Harvey

63110

St Louis

70112

New Orleans

77030

Houston

78229

San Antonio

80218

Denver

85258

Scottsdale

85710

Tucson

91010

Duarte

94305

Stanford

94611

Oakland

99208

Spokane

06520

New Haven

06119

West Hartford

62794-9677

Springfield

02114

Boston

02115

Boston

02215

Boston

87131-0001

Albuquerque

97401-8122

Eugene